<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01617772</url>
  </required_header>
  <id_info>
    <org_study_id>90-03-37-15428</org_study_id>
    <nct_id>NCT01617772</nct_id>
  </id_info>
  <brief_title>Atorvastatin, L-Carnitine and Non-Alcoholic Steatohepatitis</brief_title>
  <acronym>NALCAT</acronym>
  <official_title>Comparison the Effectiveness of L-Carnitine With Atorvastatin in Non-Alcoholic Steatohepatitis (NASH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tehran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tehran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present study was to compare the effects of simvastatin and L-carnitine&#xD;
      coadministration versus simvastatin, L-Carnitine monotherapy on liver transaminases and liver&#xD;
      elasticity in NASH patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nonalcoholic fatty liver disease (NAFLD) represents a spectrum of disease ranging from&#xD;
      steatosis to steatohepatitis (nonalcoholic steatohepatitis, NASH) to cirrhosis. Statins are&#xD;
      competitive inhibitors of Hydroxymethylglutaryl-CoA reductase, the rate-limiting step in&#xD;
      cholesterol biosynthesis. They occupy a portion of the binding site of&#xD;
      Hydroxymethylglutaryl-CoA, blocking access of this substrate to the active site on the&#xD;
      enzyme. A reduction in intrahepatic cholesterol leads to an increase in LDL receptor turnover&#xD;
      that results from an enhanced rate of hepatic LDL receptor cycling. On the other hand recent&#xD;
      studies have implicated several important cellular processes and signaling pathways that are&#xD;
      affected by abnormal lipid metabolism, resulting in specific biochemical, histological, and&#xD;
      clinical changes associated with NAFLD.&#xD;
&#xD;
      Maybe statins, as lipid lowering agents, and through their effect in reduction of&#xD;
      intrahepatic cholesterol, can affect the abnormal lipid metabolism in NASH.&#xD;
&#xD;
      L- carnitine, can improve the outcome of NASH, because it reduces lipid levels, limits&#xD;
      oxidative stress, and modulates inflammatory responses . It performs a number of essential&#xD;
      intracellular and metabolic functions, such as fatty acid transport, detoxification of&#xD;
      potentially toxic metabolites, regulation of the mitochondrial acyl-CoA / CoA ratio, and&#xD;
      stabilization of cell membranes. It has a pivotal role in the transport of long chain fatty&#xD;
      acids across the inner mitochondrial membrane.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>improvement in liver stiffness</measure>
    <time_frame>2 years</time_frame>
    <description>As measured by Fibroscan</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement in liver enzyme levels</measure>
    <time_frame>2 years</time_frame>
    <description>Difference between last and first measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse drug events</measure>
    <time_frame>2 years</time_frame>
    <description>questionnaire</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">440</enrollment>
  <condition>Non-alcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20mg atorvastatin daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carnitine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mg L-carnitine daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atoral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1000mg L-carnitine and 20mg atorvastatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identically looking placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Atorvastatin 20 mg</description>
    <arm_group_label>Atoral</arm_group_label>
    <arm_group_label>Atorvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>L-Carnitine</intervention_name>
    <description>1000mg L-carnitine</description>
    <arm_group_label>Atoral</arm_group_label>
    <arm_group_label>Carnitine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identically looking placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NASH diagnosed on the basis of the following criteria:&#xD;
&#xD;
               1. Imaging techniques showing evidence of hepatic steatosis&#xD;
&#xD;
               2. Increased alanine transaminase above 1.5 times normal (normal: 20 IU/L for women,&#xD;
                  30 for men) on two occasions three months apart.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with hepatitis B or C&#xD;
&#xD;
          -  alanine transaminase &gt; 300 IU/L&#xD;
&#xD;
          -  Participants presenting one or more causes commonly associated with secondary NAFLD&#xD;
             (drugs, surgical procedures, environmental toxins, or total parenteral nutrition)&#xD;
&#xD;
          -  Alcohol ingestion greater than 40 gr per week&#xD;
&#xD;
          -  Abnormal Lipid profile (TG&gt;500 , LDL&gt;160)&#xD;
&#xD;
          -  Patients with hypertension, diabetes mellitus, coronary heart disease&#xD;
&#xD;
          -  Fibroscan score more than 14 kp&#xD;
&#xD;
          -  pregnancy, lactation&#xD;
&#xD;
          -  Drug addiction&#xD;
&#xD;
          -  Reynolds Risk Score &gt; 10%&#xD;
&#xD;
          -  Not consenting to the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Reza Malekzadeh, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Tehran University of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shahin Merat, Professor</last_name>
    <phone>+98 917 117 3966</phone>
    <email>merat@tums.ac.ir</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Reza Malekzadeh, Professor</last_name>
    <phone>+98 912 111 4139</phone>
    <email>malek@ams.ac.ir</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pars Cohort Center</name>
      <address>
        <city>Shiraz</city>
        <state>Fars</state>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Masoud Clinic</name>
      <address>
        <city>Tehran</city>
        <zip>14117</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahin Merat</last_name>
      <phone>+989171173966</phone>
      <email>shahin.merat@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>June 8, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>May 5, 2018</last_update_submitted>
  <last_update_submitted_qc>May 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-alcoholic steatohepatitis, Atorvastatin, L-Carnitine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

